Patent intelligence · US
US 12427212
Nectin-4 binding miniproteins, conjugates and uses thereof
Nectin-4 binding miniproteins, conjugates and uses thereof
Patent details — US 12427212
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 30, 2025
- Expiration
- Sep 25, 2045
- Applicant
- Aktis Oncology, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K2121/00, A61K38/00, A61K51/088
Quick answer
US 12427212 (Nectin-4 binding miniproteins, conjugates and uses thereof) is held by Aktis Oncology, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aktis Oncology, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K2121/00, A61K38/00, A61K51/088, A61P, A61P35/00
Frequently asked questions
What is US patent 12427212?
US 12427212 (Nectin-4 binding miniproteins, conjugates and uses thereof) is held by Aktis Oncology, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12427212?
Aktis Oncology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12427212 expire?
Our index shows an expiration date of Sep 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.